PHARMACOVIGILANCE: A REVIEW OH HERBAL AND CONVENTIONAL MEDICINAL PRODUCTS

Project report submitted in partial fullfilment of the award of the degree

BACHELOR OF PHARMACY

Submitted By:

JUHI

(17SMAS102069)

IN

BACHELOR OF PHARMACY

SCHOOL OF MEDICAL AND ALLIED SCIENCES

Under the supervision of

DR.SAMEEKSHA KOUL

GALGOTIAS UNIVERSITY

(Established under Galgotias University Uttar Pradesh Act No. 14 of 2011)

APRIL, 2021

SCHOOL OF MEDICAL AND ALLIED SCIENCES

BONAFIDE CERTIFICATE

Certified that this project report "**PHARMACOVIGILANCE: A REVIEW ON HERBAL AND CONVENTIONAL MEDICAL PRODRUCT**"is the bonafide work of **"JUHI (17SMAS102069)**" who carried out the project work under my supervision.

SIGNATURE OF DEAN **SIGNATURE OF SUPERVISOR**

Approval Sheet

This thesis/dissertation/report entitled " PHARMACOVIGILANCE: A REVIEW ON HERBAL AND CONVENTIONAL MEDICINAL PRODCUTS" by JUHI is approved for the degree of Bachelors Of Pharmacy

Examiners

_____

_____

Supervisor (s)

_____

_____

_____

Chairman

_____

Date:_____

Place:_____

Statement of Project Report Preparation

1. Thesis title: PHARMACOVIGILANCE: A REVIEW ON HERBAL AND CONVENTIONAL MEDICINAL PRODUCTS

1. Degree for which the report is submitted: BACHELORS OF PHARMACY

3 Project Supervisor was referred to for preparing the report.

4. Specifications regarding thesis format have been closely followed.

5. The contents of the thesis have been organized based on the guidelines.

6. The report has been prepared without resorting to plagiarism.

7. All sources used have been cited appropriately.

8 The report has not been submitted elsewhere for a degree.

Signature of Student:

Name:Juhi

Roll No.: 1712102031

Statement of Preparation:

Every student have to submit the statement of thesis preparation

TABLE OF CONTENTS

ABSTRACT

Defining pharmacovigilance has never been more important in an era when the number of accelerated and limited review paths for recently published brand-name medications and biosimilar medicines to treat critical and life-threatening diseases is on the rise. Pharmacovigilance in the twenty-first century is defined as the systematic screening of the pre-marketing study and post-marketing surveillance processes, which involves the use of medications in everyday life, rather than just discovering, reporting, and treating adverse occurrences connected with previously approved and marketed drugs. Herbal medicine is, in reality, the earliest, most traditional, and least expensive medical system available to low-income and local populations. As a result, the medical system was and still is a supporter for those seeking to cure and overcome little or serious health issues. The conventional technique, unlike the herbal medical system, is more scientifically verified and researched, as well as more controlled. Each system seems to have its own set of advantages and disadvantages. Pharmacovigilance is equally crucial for herbal and conventional medications. The entire world should work to guarantee that medical items are of high quality, safe, and effective.

LIST OF TABLES

LIST OF FIGURES

LIST OF ABBREVIATIONS

1) PV- Pharmacovigilance
2) WHO- World Health Organisation
3) ADR- Adverse drug reaction
4) PvPI- Pharmacovigilance Program of India
5) CDSCO-Central Drugs Standard Control Organization
6) TRIPS-Trade Related Intellectual Property Rights
7) UMC-Uppsala Monitoring Centre
8) ICH-The International Council for Harmonisation
9) EU-European Union
10) SRS-Spontaneous reporting systems
11) BCPNN-Bayesian confidence propagation neural network
12) MGPS-Multi-Item Gamma Poisson Shrinker
13) FDA-Food and Drug Administration
14) GP- general practitioner
15) GPRD-General Practice Research Database
16) MHFW-Ministry of Health and Family Welfare
17) ICMR-Indian Council of Medical Research
18) MCI-Medical Council of India
19) NGO-Nongovernmental Organizations
20) DCGI-Drug Control General of India
21) MNC-Multinational Corporations

22) AMC-ADRs Monitoring Centers

23) ICSR-Individual Case Safety Reports

24) CHC-Community Health Centres

25) EMEA-European medicine evaluation agency

26) ENCePP-European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

27) CHMP-Committee for Medicinal Products

28) RMP- Risk Management Plans

29) LIM-Lareb Intensive Monitoring programme

30) GPP- Good Pharmacovigilance Practice

31) OTC-Over the Counter

32) IOM-Institute of Medicines

33) NCC-National Coordination Centre

Pharmacovigilance: A review on herbal and conventional medicinal product

1. Introduction

W. McBride, a physician in Australia who came first to suggest a causative correlation amongst severe foetal abnormilities(phocomelia) and thalidomide, a medication used when a women is pregnant, published a letter (case report) in the Lancet in December 1961, which officially established pharmacovigilance (PV). In pregnant women, thalidomide was utilized as an antiemetic and sedative specialist [1,2]. The World Health Organization (WHO) launched the "Global Drug Monitoring programme" in 1968, a trial initiative intended at centralising information on harmful drug reactions around the world (ADRs). The primary aim of the "WHO Program" was to identify the earliest Pharmacovigilance signals that were available. PV was coined by a party of people of French toxicologists and pharmacologists in the mid-1970s to describe practises that promote "the evaluation of the dangers of possible side effects involved with opioid treatment"[1,3].

PV is the science of gathering, tracking, testing, analysing, and reviewing knowledge from the field of medicine professionals and people who are sick about the repercussions of drugs, biology samples, health supplies, blood transfusions, herbal medicines, vaccines, conventional and alternative therapies with the aim of discovering new information about product hazards and avoiding patient injuryThe task of maximising drug protection while retaining consumer confidence has become exceedingly difficult. Throughout the lifecycle of a medication, from production to post-market, biotechnology and pharmaceuticals firms not just have to track however , assess and control medication risk. [4,1].

In January 2005, the National Pharmacovigilance Program of India(PvPI) was recognised by the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, in partnership with the Indian Pharmacopeia Committee, Ghaziabad.

Aim of Pharmacovigilance

- Improve patient treatment and protection by using medications and other both medical and non-medical procedures.

- Enhance public wellbeing and welfare when it comes to drug administration.
- Promote pharmacovigilance awareness, research, and professional training, as well as good public relations.

When a drug is sold and prescribed to vast audiences around the world and abroad, no amount of precaution and vigilance in the pre-clinical and clinical research phases will guarantee full safety. Since clinical trials typically include tens of Millions of patients, rarer side effects, and negative drug reactions (ADRs) are quite often unidentified before a medicine is introduced to the marketplace. To classify the relationships between drugs and ADRs, post-marketing PV employs techniques such as data mining and case report analysis. During the manufacture of a medication process and later on in a branded drug's life cycle, drug regulatory agencies are responsible for providing a well-established PV system to track ADRs. [1,5].

The organizations and regulatory bodies to access the safety criteria and take corrective measures, such as medication removal or banning. The emergence of a brand-new application system Trade Related Intellectual Property Rights(TRIPS) and Services are a term used in the Indian biopharmaceutical industry, forces India to stop copying proprietary goods and selling them without permission from the innovator company. As a result, Indian pharmaceutical and biotech companies' research and development efforts in the coming year should hopefully result in new drugs based on preclinical and clinical data developed primarily in India..[1]

Despite variations in organisation and growth, all pharmacovigilance programmes face similar challenges in drug safety surveillance; to meet these challenges, they must accept new opportunities in five interrelated areas: public engagement, cooperation and collaborations, integrating informatics, taking a global approach, and evaluating the impact of efforts.. In general, advancements in science and technology, together with higher societal standards, have altered the essence of these problems and the field's response to them. [6].

Since 1970, the WHO has been at the forefront of addressing the need for drug safety monitoring. The WHO International Drug Monitoring Network has developed a coordinated pharmacovigilance programme The Uppsala Monitoring Centre(UMC), in cooperation with the WHO Collaborating Centre in Sweden, This involves creating a programme for sharing safety data, maintaining the global WHO archive of adverse drug reaction (ADR) reports, and disseminating numerous drug safety surveillance

guidelines. It also seeks to bridge the divide between business and regulatory bodies. In an immediate response to the need for pharmacovigilance, the WHO extended its efforts to encourage natural medication analysis for defence within the context of the WHO Global Drug Monitoring Programme. [7]

Herbal medicines are made up of plants or parts of plants and are used to treat accidents, diseases, and illnesses, as well as to encourage health and healing. Natural products seen to be the world's the earliest method of medical treatment. [8,9,] . Natural products are accomplished, branded medicine items which includes chemical compounds, aloft or subterranean sections of the plants, or some other plant substance or variations of plants, according to the World Health Organization (WHO). Basic standards for assessing the safety, efficacy, and accuracy of herbal medicines have been established by the World Health Organization (WHO). According to the World Health Organization, about 81 percent of the global population currently uses herbal medicine for primary health care. [10]

Herbal preparations are also used as disinfectants, anti-diabetics, anti-fertility, anti-arthritic, anti-aging, laxatives, anti-depressants, and anxiolytics, among other things. [9].

Furthermore, older adult people would be more likely to use both traditional and herbal medicine. This group is often more likely to suffer from chronic illness, which frequently necessitates the use of increasingly complex conventional drug therapy. As a result, the risk of herb-disease and herb-drug reactions rises as people get older. There is currently a scarcity of research, especially clinical trials, evaluating the use of herbal medicines. This, combined with the continued emergence of new conventional drug treatments, increases the amount of uncertain outcomes when these two treatment methods are combined. Herbal medicines are not limited to the same extent as prescription drugs in many countries, including the United States. Clearly, a concerted effort is needed to perform the requisite clinical trials to investigate the effectiveness and safety of herbal medicines, both alone and in combination with traditional drug therapies. [11]

1.1 The WHO international drug monitoring program[12]

The Program now includes a network of more than 70 national pharmacovigilance centres that run independently but are organised and aided by the WHO and the UMC. The UMC (Uppsala Monitoring Centre) is in charge of the global WHO

database, which receives all case reports from national pharmacovigilance centres. The UMC uses the global WHO database to identify/detect new adverse reaction signs from composite data and to relay risk reports to national pharmacovigilance centres and other stakeholders involved in drug safety. [13].

1.2 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH)

Medications must be approved in order to marketing based on common standards such as consistency, protection, and effectiveness, as well as local public health needs. Scientific criteria for investigating consistency, protection, and effectiveness should also be universal in order to make efficient use of resources and avoid delays in the delivery of medicines The International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use was created (ICH) between authorities and industry in the In 1990, the European Union (EU), Japan, and the United States took a big step toward this goal. Since then, the ICH has issued more than 50 guidelines, six of which are devoted to pharmacovigilance. They contribute to the management and rapid reporting of individual adverse drug reaction (ADR) events, including electronic formats, as well as the frequent reporting of global data and pharmacovigilance preparation. Their gains must be seen in the context of the three ICH Regions' attempts to enhance pharmacovigilance. Most recently, this has included the application of risk management principles, illustrating modern proactivity thinking in pharmacovigilance[14].

Some types of issues pharmacovigilance has to deal with, several new instances of safety issues as well as actions are taken place.[15]

1.3 Safety concern

Table 1. Drug safety issues and their evidence in Europe ince 1995

Medications	**Issues about safety**	**Proof of importance**	**Regulatory intervention**
Trovofloxacin	Liver damage	Unplanned adverse drug effects	Removed from consideration

Tolcapone	Liver damage	Unplanned adverse drug effects	Discontinued
Cisapride	The risk of life-threatening cardiac arrhythmias increases with a prolonged QT period.	Unplanned adverse drug effects	Approvals to enroll patients were eventually revoked.
Bupropion	Epilepsy as an interaction between drugs	Unplanned adverse drug effects	Changes in posology, Alerts
Cerivastatin	breakdown of muscle tissue.	Unplanned adverse drug effects	Removed from consideration
SSRIs	Children's depressive actions	Clinical tests	Medical advice is given along with the precautions.
Hormone replace therapy	Long-term cardiovascular disease risk and cancer	Epidemic research	Limitations on signal and alerts

2. Methods used in pharmacovigilance

The practises that are considered an act of pharmacovigilance might possibly be categorised into three categories.: Regulatory, business, and academic institutions are all involved. The aim of governing pharmacovigilance is to provide the public with pharmaceuticals that have a favourable benefit-to-harm profile. In this context, some of the issues surrounding post-market regulatory monitoring will be addressed, accompanied by an explanation of the methods used to identify new ADRs..[15]

2.1 Data from clinical studies were inadequate to assess drug risks.

A clinical trial is the most common technique for gathering data on a product in is collected the pre-market phase. There are three stages of pre-marketing clinical trials. Studies in the third stage are frequently blindfolded randomized clinical tests, and will called the most robust method to deciding whether a treatment and a result have a cause-and-effect relationship. This study design, on the other hand, is not ideal for monitoring a drug's safety. Because of the small number of patients that participate, it is difficult to classify ADRs that occur only infrequently. Another downside of clinical trials is that the attributes of subjects not at all necessarily correlate in relation to the peculiarities of the number of people in which they will be put to utilize later; as a result, extrapolating outcomes derived from clinical tests to the general people can be difficult. [16]. It's particularly important to the aged, women, and people from minority ethnic groups. [17,18]. In the post-marketing phase, the medication will be closely monitored which is needed to research unusual ADR. ADR with a prolonged period delay, and ADR in particular number of people. There are two types of post-market research: illutrative and systematic. Illustrative research aim to explain the incidents that take place and linked to medication noxiousness and effectiveness by generating hypotheses. Analytical experiments are used to test theories and establish correlations or open relations amongst known outcomes and specific medications, as well as to quantify the magnitude of these outcomes. Qualitative study are often utilized in post-market research for the reason that it can produce theories that can be used as the basis for more analytical studies. [19]. Here, two types of descriptive research will be discussed: spontaneous reporting and intense monitoring. Analytical experiments use a variety of approaches, including case-control studies, cohort studies, and clinical trials. Data that has been obtained in a consistent and systematic manner must be available in order to perform retroactive group and case-control research.

2.2 Spontaneous reporting

Spontaneous reporting systems (SRS) were developed, and they have since been the most popular method of gathering post-marketing data on drug safety. The primary goal of SRS is to quickly recognise recent, rare, and serious ADRs. A mechanism that encourages physicians, healthcare personnel, and patients to report potential adverse drug effects to a pharmacovigilance centre is known as a random notification

system[20-22]. The pharmacovigilance center's job is to collect and analyse data, as well as to alert stakeholders to possible risks when new ADRs are detected. The pharmaceutical industry also uses spontaneous monitoring to collect data on their products . A SRS allows for reasonably low-cost monitoring of all medications in the marketplace over their whole cycle of life. The main criticism of this approach is the possibility of selective reporting and underreporting. False reporting will result in the incorrect consequences that a specific threat does not exist, in the meantime selective reportage of perceived threats can offer the a visual image of threat which do not occur. False reporting and limited reportage, on the other hand, can be seen as benefits. Since only the most serious and unusual cases are registered, new ADR signals are easier to identify due to the individual informing the response has presently identified which might be a current security issue. [23]. It's impossible to determine cause-and-effect relationships or reliable occurrence rates with an SRS, and it's also impossible to comprehend health risks or illuminate use trends. Despite the fact that some critics argue that spontaneous reporting is not the best tool for tracking drug protection, it has proved its worth over time. Between 1999 to 2001, eleven goods were removed from the UK and US markets.

2.3 Data mining in spontaneous reporting

Data mining techniques, on the other hand, have become increasingly important in recent years. The process of analysing data from different perspectives and extracting valuable information is known as data mining Despite the fact that the procedure of the different data mining techniques used in PV varies, they're all there to convey how much the overall number of reported certain instances varies from the amount of predicted instances. [24]. The Bayesian confidence propagation neural network (BCPNN) approach used to illustrate reliance in the collected data. To evaluate all observed ADR combos, this method employs Bayesian statistics applied in a neural network model. In comparison to standard reporting of possible adverse effects, experimentally surprisingly good relations in the report are emphasized. The WHO Collaborating Centre for International Drug Monitoring employs this data mining technique. [25] The FDA uses a similar technique called the Multi-Item Gamma Poisson Shrinker (MGPS) to mine their random report database. The MGPS algorithm calculates signal scores for sets of medications and incidences that are substantially

more common than their handful relationships might expect, as well as greater (e.g. triplet, quadruplet) assemblages of medications and incidences. [26].

2.4 Intensive monitoring

In New Zealand(Intensive Medications Surveillance Program)) and the United Kingdom late in the 1970s and earliest on 1980s, a new type of constant monitoring was created (Prescription Event Monitoring). Prescription data is used to classify consumers of a specific drug in these intensive surveillance systems. The drug's prescriber is questioned about any adverse events that occurred when the drug was being controlled. Intensive screening is based on a non-intrusive observational analysis, and differs from random reporting in that the former only measures individual drugs over a short period of time. Effective surveillance offers medical evidence from the actual world without using any incorporation or elimination criteria in the assemblage process, due to its non-interventional nature. It is not harmed by the types of incorporation and elimination conditions used in clinical tsest, removing the possibility of selection bias. In addition, intensive surveillance programmes allow for the estimation of the occurrence of adverse events, allowing for the quantification of the probability of such ADRs. However, there are several drawbacks to this strategy. It is unclear what percentage of adverse effects are not reported to physicians. In addition, instead of real injury rates , the survey yield confirmed case rates.

While the Effective Surveillance technique was introduced over a quarter-century ago,it has recently resurfaced as a topic of interest. It's listed as a tool for enhancing the method of pharmacovigilance [27].

2.5 Studies based on databases

A research must be conducted so as to evaluate a theory. Case-control studies and cohort trials are two approaches that can be used to perform the research. Power considerations and research architecture are two of these methods' drawbacks. In order to perform retroactive group and case-study research, information that has been obtained in a consistent and customary manner must be made easily attainable.[28]

2.5.1 Database of Primary Care Research

In the United Kingdom, the general practitioner (GP) coordinates nearly all medical care, and information from this section offers a nearly complete description of a

sufferer, his conditions, and mediacal care. GPs that are part of the GPRD, Per year, the GPRD collects data from about 3 million patients (about 5 percent of the UK population). In expressions of age, sex, and regional distribution, these sufferes are fairly spokesperson of the general public of the United Kingdom. Demographics (age and gender), clinical diagnoses received as part of routine treatment or as a result of hospitalizations, appointments, or emergency care, as well as the date and place of the case, are all collected. Unrestricted text, referrals to health-care facilities and clinicians, all medications, including the dates of the prescription, the effectiveness of the product, the quantity, and the dosages directions, inference for care for all treatments that are recent, and incidents directing to medication or treatment retractions are also options. Vaccination records, as well as other personal details such as Smoking, height, weight, immunizations, pregnancy, birth, and death ,date of entry, date of exit, and research lab test outcomes, are gathered. [29-31]

2.5.2 PHARMO

The PHARMO system was created in the Netherlands in the early 1990s. Based on the client's date of birth, gender, and GP code, PHARMO connects a residential pharmacy as well as data from the hospitals in a particular area. Drug distribution documents from neighbourhood clinics and documents of patient discharge for around 2 million individuals in the Netherlands have also been added to the system. PHARMO has recently been related to other information sources, including main health services records, community questionnaires, genetic factors and laboratory study records, cancer and injury registries, mortality rates records, and financial results. Since existing databases are used and connected, the lowest common data in the method is well-defined that enables estimates of frequency and occurrence. It is also comparatively inexpensive. Investigational trials, case-control studies, as well as other types of clinical data to evaluate drug-related side effects are all conducted using the PHARMO database The database has previously been used for research on substance use, treatment adherence, economic effects, and adverse drug reactions (ADRs). [32,33].

2.5.3 Cohort study

A research that recognises identified populations and follows them over time to see how disease rates change. In general, a cohort study compares patients who have been

exposed to non-exposed patients or patients who have been exposed to a specific form of exposure.

3. Current scenario and future prospects of pharmacovigilance

India is a large country with over 6,000 licenced pharmaceutical companies and more than 60,000 marketed compositions. India is the fourth biggest producer in the world, of pharmaceutical products and is quickly becoming a centre in order to conduct clinical studies. Since Several new medicines are being implemented in India, therefore a great requirement to strengthen the PV program in order to safeguard the Native peoples the possible damage that any of the new medicines may produce. (Yerramili, 2014)[34].

Inspections in all Indian pharmaceutical firms ought to be ordered to keep and send the Description of Pharmacovigilance System report to the DCGI, which will form the basis for future pharmacovigilance inspections. A high-level conversation should be organised with a variety of stakeholders, including the Ministry of Health and Family Welfare (MHFW), the Indian Council of Medical Research (ICMR), the Medical Council of India (MCI), the Pharmacy Council, the Nursing Council, the Dental Council, Pharmaceutical Companies, Consumer Associations, Nongovernmental Organizations (NGOs), and Patient Groups should be started for the purpose to educate them about in what manner India's Drug Control General (DCGI) intends to strengthen and creatre a comprehensive PV scheme. Increase the number of qualified scientific and medical evaluators in the DCGI office for pharmacovigilance. Officials employed in the DCGI's pharmacovigilance sector, as well as in the peripheral, district, and zonal centres, should receive advanced training in all aspects of pharmacovigilance. Training should be planned twice a year as part of this ongoing operation. Producing a single method for reporting adverse events that can be utilised by all in the country (Salim. 2015)[35] .

Maintaining a common database for each pharmaceutical industry should include a list of all new drug indications in the database, which should be kept up to date by regulatory agencies and pharmaceutical companies. All new problems should be closely monitored. In these situations, pharmaceutical companies can have a meeting with the DCGI to discuss risk management strategy for the concerns about protection at hand, as well as how they plan to implement successful measures to minimise the

risks. Pharmacovigilance training and certification for medical students, healthcare professionals, and nurses (Elhassan, 2015)[36]. There are many clinical research courses offered by different organisations, but no pharmacovigilance courses are currently offered in the region. A pharmacovigilance syllabus should be included in the pharmacology and medicine curricula by all stakeholders, including the MCI, so that physicians receive adequate theoretical and realistic instruction. Nursing staff and healthcare professionals are also important members of the healthcare team, so they also should be educated in pharmacovigilance so that they can detect and track adverse drug reactions (ADRs) in the future. An education and training programme covering all aspects of pharmacovigilance (via distance education and face-to-face learning). These are intended for pharmaceutical firms engaging in research and production, especially those engaged in new drug research, as well as the medical industry, pharmacists and chemist-druggist trades, and patients, to be diligent in identifying ADRs and reporting them to Indian regulatory authorities, who will then investigate and take effective corrective action. As information technology (IT) progresses, collaboration with pharmacovigilance organisations is becoming more important in order to increase drug safety, new opportunities for national and international partnerships to improve post-marketing monitoring systems and enhance the security of drugs have emerged. The Uppsala Monitoring Center (UMC) is an example of Global cooperation to create a standardised post-marketing monitoring collection of information. The system is focused on the sharing of harmful reaction data between 80 wide drug surveillance centres. Via the internet, information is transferred, processed, and accessed in a proper and safe manner. [37]. The UMC archive contains over four million documents and a vast number of data areas with the support of experienced private companies, a database that is identical can be developed for the DCGI based on safety records from clinical trials and post-market surveillance. A core team of experts of representatives in India was established in order to provide a network of pharmacovigilance and pharmacopeidemiologists from multinational corporations (MNCs), Pharmaceutical industries in India, and regulating body staff will need to be established (DCGI). Collaboration with the IT industry in the creation of a strong PV framework for India The computer applications systems formulated can be utilized for data assemblage and analysis, assessing drug use levels in different disease fields, enforcement, prescription, Drug reactions and mistakes that contribute to ADRs, and more. (Patil, 2014)[38].



Fig 1: Framework of Governance

ADRs Monitoring Centers (AMCs) have been established at 179 Medical Council of India accredited medical schools and corporate hospitals across the country. For operational and logistical purposes, these centres are covered by four offices in different zones of the Central Drugs Standard Control Organization (CDSCO). These AMCs are connected to a global network (reporting through VigiFlow; WHO-Uppsala Monitoring Centre [UMC] software). These AMCs use WHO-VigiFlow UMC's tools to report ADRs to the NCC. (Sweden). Over the course of five years, the NCC has been instrumental in raising awareness among medical practitioners about the importance of reporting adverse drug reactions (ADRs), with over 1,49,000 ADRs registered by December 2015.[Fig2] India currently contributes 3% to the WHO's global archive of Individual Case Safety Reports (ICSRs).[39]



Fig2. Growth of database of Safety Reports for Individual Cases since the inception of the Pharmacovigilance Programme of India

The regional centre receives information on adverse drug reactions from both primary health care centres (PHCs) and community health centres (CHCs). The treatments derived from natural sources were thought to be healthy and free of adverse drug reactions .However, the heart of ayurveda, "Charka Samheta," ADR can arise with herbal medicines, according to research as well if they are formulated and delivered incorrectly. As a result, it was important to provide PV for herbal drugs in order to include ADR data for AYUSH drugs in accordance with WHO guidelines. (Srivastava, 2011)[40,41] .



Fig 3: Curriculum for Pharmacovigilance in India



Fig 4: Pharmacovigilance work

Three publications have been particularly important in recent years when it comes to offering advice on the future of pharmacovigilance. The initial, written in 1997, is the Erice Proclamation on Lucidity.[42] As in this decleration, pharmacovigilance specialists from around the whole planet, covering various industries, highlight the importance of contact in drug safety with following remarks:

- The public's wellbeing must be served by drug safety facts.
- Both the general public and health-care practitioners need to be updated about how to use drugs correctly, including how to interpret safety data.
- All evidence required to identify and comprehend threats and advantages must be publicly accessible.
- Each nation requires a programme of solitary experts to make sure that safety data on all obtainable medicines is properly compiled, practically analyzed, and made available to all.
- Drug safety management inventiveness must ensure that emerging issues are quickly identified and addressed, as well as that knowledge and solutions are easily shared.

This statement was accompanied by the Erice Manifesto for Global Improvement of Medication Protection in Patient Care in 2007[43]. The Erice Manifesto identifies the issues that must be faced in order for research to continue to progress and be useful, including:

- Active patient and public participation in the central discussion about the dangers and benefits of drugs, as well as in decisions regarding their own care and wellbeing.
- The design of innovative methods for gathering, evaluating, and sharing knowledge about the protection and efficacy of medicines; open review of this information and the decisions that derive from it.
- The development of knowledge from other disciplines on how to develop phamacovigilance techniques, as well as broad technical, public and formal cooperation.
- The development of intending, organized, massive global help among policymakers, administrators, researchers, physicians, Patients, as well as people in the community, centred on the demonstrable public health advantages of pharmacovigilance.

The third paper, written by Waller and Evans in 2002, has had a significant influence on how in future pharmacovigilance will be carried out Excellence, the scientific process, and honesty should be the pillars of pharmacovigilance. The paper identifies five components that are thought to be necessary for achieving excellence. Best evidence based on a process, rigorous decision-making in science, and efficient equipments to provide security of health of the general public are three of them. These processes are supported by the other two components, scientific advancement and audit, which recognize that excellence cannot be accomplished solely by procedure. [44].

4.Developments

4.1 International developments

Regulatory authorities have been changing their processes in recent years to keep up with pharmacovigilance trends, with an emphasis on becoming more proactive.

4.1.1 Europe

The Heads of Medicines Agencies drafted a paper titled " The Action Plan's Execution to Advance the the European Strategy for Risk Assessment " in 2005. The EMEA(European medicine evaluation agency) reported a documentation in July 2007 that talked about the accomplishments that had been made thus far. These

accomplishments comprised of the introduction of legislative instruments for controlling the Medicines' security and administrative actions. The following points were highlighted in particular:

- Risk management programmes are implemented in a systematic manner.
- Improving the EudraVigilance database in order to strengthen the random reporting scheme.
- Starting the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) plan to improve medicinal product tracking.
- Multi-center post-authorization protection trials are being conducted.
- Improving the EU Pharmacovigilance System's organisation and service.

In the name of the European Union Agency, a public discussion entitled "A Plan of action to Better Protect community Health by Enhancing and Rationalizing EU Pharmacovigilance" was released in December 2007. This paper outlines the European Union's legislative policy as well as key legislative initiatives. Changes to the law are required in the following areas: Rapid and firm decisions on safety challenges, clarification of duties and responsibilities for industry and regulators, expanded relevance of risk-management preparation, and higher-quality non-interventional safety research, enhancing drug safety, lucidity, and exchange of knowledge, consisting of better product safety alerts details to ensure that medications are used safely, simplifying of ADR reportage, including the introduction of patient feedback. [45].

4.1.2 The USA

After the removal of rofecoxib in the United States, the Food and Drug Administration (FDA) has had a tough time. The biggest concern is that the FDA is not as effective as it should be in protecting the public from drug threats. The FDA launched several measures in February 2007 based on the IOM study to increase the safety of prescribed medications. [46]. These programmes are divided in four classes. The initial is to increase the amount of money available for drug safety activities. Some analysts advocate removing user fees because they believe the agency is too reliant on industry funding. The FDA requires administrative resources to help ensure drug protection, so the second type of suggested change is new authority for the department. The enhancement of post-marketing monitoring is a third part of the reform. It is essential to develop a customary, comprehensive method for successful

population-based drug development monitoring that can detect possible safety issues.Lastly, the FDA's administration procedures and safety oversight must improve. [47].

The Prescription Drug User Fee Act is a federal law that imposes fee on people, which requires the pharmacy company to send funds straight to the FDA, was introduced by the Senate to raise fees to the FDA by almost $400 million dollars Furthermore, this change will grant the FDA new power to require industries to conduct strict safety trials on medicines until they are sold, as well as fine companies that do not follow through with their post-marketing obligations. Nonetheless, when it came to reforming the FDA's a framework the plan to establish a separate organisation to regulate drug safety was defeated by a majority with one support.[48-50]

4.2 Methodological developments

4.2.1 Lucidity

Lucidity is essential for the upcoming pharmacovigilance, according to the Erice Declaration [51] and Waller and Evans [52]. Transparency around ADRs has improved in recent years. Clinical trial registration would allow for the required monitoring of trials in order to make sure complete and unprejudiced reporting for the population good. [53]. A number of nations, including Canada, the Netherlands, and the United Kingdom, have made reports from the spontaneous reporting process publicly accessible to the general public in their databases.

4.2.2 Conditional approval

Whenever it gets to supplemental post-market reports, both the FDA statement and the statement from the European Union mentioned formerly indicate that promoting authorization occupants ' enforcement requires to be strengthened. A time-limited conditional approval could be one solution to this issue, as it would put pressure on manufacturing companies to perform and disclose more research on safety. [54]

The EMEA has implemented a state marketing authorization within the European Union. For services that meet a particular patient need, the Committee for Medicinal Products for Human Use (CHMP) grants state marketing authorization. Products for severely crippling or life-threatening illnesses, as well as emergency medicinal products, are examples.

A variety of standards must be met, including:

1. A commodity with a favourable risk-benefit ratio.

2. The likelihood that the candidate will be able to offer complete clinical information
3. Unfulfilled patient requirements are met
4. The public health value of instant supply of the pharmaceutical commodity outweighs the risk associated with the lack of additional evidence.

Conditional marketing authorizations are renewable and have a one-year validity period. The holder must conclude existing experiments or perform new ones with the aim of ensuring that the risk-benefit ratio is in balanced and is favourable. Furthermore, strict obligations in regards to the processing of pharmacovigilance data can be enforced. The permission isn't supposed to be conditional forever. Rather, once the missing data is given, a structured marketing authorization should be able to take its place. A conditional marketing authorization would enable medications to meet patients with unmet medical needs earlier than they would otherwise be able to, as well as ensure that additional data on a medication is produced, published, evaluated, and reacted to.[15]

4.3 Plans for risk control

The implementation of risk management plans (RMPs) [55] is another move toward more effective post-marketing surveillance. These RMPs are to be developed for the purpose to classify, characterize, avoid, or reduce the threat associated with pharmaceutical products, as well as to assess the efficacy of those interventions. A RMP may be required at any point during the life cycle of a product, such as during the periods of pre-authorization and post-authorization. Any novel active ingredients, major improvements in developed products (e.g., new form/route of administration), current products added to new communities, important new signals, or an unknown threat must be recorded in an RMP.

The EU Plan for Risk Assessment is divided into two sections: the initial includes a "security definition and pharmacovigilance strategy," while the second section includes an assessment of the requirement for risk minimization activities, as well as, if applicable , a risk-reduction planA risk minimization strategy is only needed when the standard information provided by a drug's description of characteristics of the commodity is deemed inadequate. RMPs must be revealed to the public and readily approachable to researchers, experts, and patients if they are to play a significant role in pharmacovigilance.

4.5 Involvement of patients

The patient's role in pharmacovigilance has also become more prominent. Patients are drug users, and the ultimate aim of pharmacovigilance practices is to ensure that they use medications safely. Patients will now report ADRs to the spontaneous monitoring scheme in a growing number of countries. [56] Following the implementation of client reporting as part of the spontaneous reporting plan in 2004[57], Lareb, the Dutch Pharmacovigilance Centre went even further in 2006, introducing a thorough examination surveillance plan that used patients as a source of knowledge. The prescription-event tracking technique is used in the Lareb Intensive Monitoring programme (LIM), in which patients are categorised based on prescriptions. When patients take the medication For the first time, it's being researched, their pharmacies identify them as eligible. Patients can enroll on the LIM website and will receive questionnaires asking for adverse effects within a certain period of time. The framework is entirely web-based, making longitudinal data collection possible. [58]

5.Future Prospects

Over the last few years, regulatory progress has been made. However, it has yet to be seen if these advances have resulted in improved pharmacovigilance practises. It is important for academics to develop new approaches that can improve the existing framework to further develop pharmacovigilance as a research. Detecting emerging ADRs and, if appropriate, implementing regulatory measures to safeguard the public's welfare, such as updating the overview of characteristics of the commodity or removing the medicine from the marketplace, has been the focus of pharmacovigilance as we are aware of it now. PV has a major target. It is crucial to provide information on the efficacy of drug active surveillance .When developing new approaches for successful post marketing monitoring, it's necessary to keep in mind that full and reliable information on any Serious recorded incident is essential. While spontaneous reporting is useful for producing signals, it is less useful for defining Due to the small number of reports collected for a particular association, patient characteristics and risk factors were overlooked. PV procedures must also be capable of identifying which patients are in threat of experiencing a negative medication response (ADR) . Individualized health risk for the incidence of such ADRs may be established using pharmacogenetics [59]. Currently, the DCGI must work effectively to strengthen PV by incorporating Good Pharmacovigilance Practice (GPP) into the systems and practices in order to better ensure that all regulations are followed and

improve post-marketing security and clinical research safety monitoring. Post-marketing PV is actually a difficult process for both the industry and regulatory authorities (Ghewari, 2014)[60]. The modern patient is well-informed about his illness and desires to take an active role in his care. As previously discussed, the value of patients as a source of knowledge on adverse drug reactions has been recognized in some countries. Patients in these countries may use the spontaneous reporting method to report adverse events. Consumer awareness will continue, and pharmacovigilance will need to focus on this community as the originator of knowledge in the future, furthermore to more conventional groups including medical practitioners. While non-serious cases are screened less often than serious incidents, they are also critical in comparing differences in health. GlaxoSmithKline has established a powerful modern pharmacovigilance strategy (PV), combining PV that is based on an event approaches with information and disparity analysis software. BorjaOliveira (BorjaOliveira, 2015) [61]. These tools are part of a system design that enables in-stream analysis, safety problem monitoring, and information management. By the productivity and offering new analytical capabilities, this cutting-edge method and processes would aid in the advancement of PV. Consumer reporting will be strengthened by transparency and collaboration, which are important moves toward engaging customers more in PV. (Kalaiselvan, 2014)[62].

One way to do this would be to use patients as a source of knowledge more than has been done previously; this strategy would be invariable with the increasing client interest in drug security..[15]

6. Conventional Medicine And Herbal Medicinal Products

Table 2. Comparison between Herbal and Conventional drugs

S.No.	**Conventional Medicine**	**Herbal Medicine**
1.Historical Background	The use of foxglove plant extract to cure dropsy is thought to have started conventional medicine or modern therapeutics in the 1250s. The system is reliant on drugs that have been synthesised and produced.[63,64,] Following that,	Herbal therapy has been discovered to have been used for a long time, dating back to ancient times. It is a medicinal method that is based on the therapeutic ability of natural sources, specifically plants and different parts of plants such as herbs, roots, berries, barks,

	advancements in production, quality control, diagnostics, and treatment aided the allopathic system's development. Recently, with the updating of legislation and regulatory authorization, there has been improvement in terms of device consistency, protection, and performance.[65] As a result, the aim of this research is to look at details about the creation and comparison of the two medical systems. As a result, the published analysis and results are expected to yield an impartial and acceptable conclusion. [66]	flowers, and leaves etc. Herbal therapy has been largely replaced by the allopathic medical system in recent years. The Indian medical systems of Ayurveda, Siddha, Unani, and homoeopathy are among the world's wealthiest and oldest herbal medicine-based treatment systems. The bark of the cinchona tree was used by South American Indians to cure chills and fevers. Europeans were also using the same herb to cure malaria. [67,68]
2.Treatment Perspective	The conventional healthcare method is based on scientifically validated tests, methods, and procedures. In the treatment of various ailments and diseased conditions, it employs conventional, semi-synthetic, and modified medicines with proven effectiveness, protection, and efficiency. It focuses on the real illness that affects the body and defines good health to be a state in which an individual is free of disease. The pharmaceutical method makes use of medicines that are properly approved by numerous international and local regulatory authorities in terms of regulation, use, and commercialization. [69]	Herbal therapy is used to treat a holistic approach to life rather than a specific illness or ailment. It is concerned with the body's, mind's, and environment's state of equilibrium or harmony.[70] According to the study, herbal remedies are widely used to cure a variety of diseases all over the world. One of the system's major flaws is the lack of systematic approaches to evaluating and illustrating the efficacy, effectiveness, protection, and consistency of herbal medicine .[71]
3.Concept and Approaches towards Disease Management	The conventional medical system assumes that treating an illness or condition by concentrating on its symptoms is the best way to go. As a result, each disease or	Herbal treatment looks at the body as a whole and seeks to boost the body's ability to cure itself by boosting the immune system. It strikes a balance between a methodical,

	group of diseases, as well as their side effects, has a specific drug that is thought to be the best way to cure the disease or conditionSince the cure depends on the condition, there is little or no individualization for the patients in conventional medicine. [71,72]	normal, and unique treatment and prescription approach. Herbal drugs are administered as customised medications, meaning that the treatments are adjusted to the specific needs of each patient. It considers how each person differs from others in many aspects, such as how they speak, make choices, behave, or their susceptibility to diseases .[63,67]
4.Problems associated with Safety concerns	The conventional medical practise employs a complex set of procedures that include preclinical, clinical, and postclinical studies that examine not only the potency and efficiency of drugs, but also their safety and potential toxicity. It entails a variety of quality control procedures that ensure the absence of toxicity in medicinal substances prior to acceptance and also use, as well as ongoing monitoring of their use once they are on the market. [65]	Herbal treatment, on the other hand, comes from herbal sources, meaning there may be less side effects. However, only a few cases of serious physical complications such as allergic reactions, liver or kidney failure, cancer, and even death have been identified as a result of them.[73]. The majority of naturopathic remedies currently on the marketplace haven't subjected to a drug-approval review to determine their safety and efficacy. Mercury, lead, asbestos, corticoids, and radioactive unprocessed matter are all present in dangerous concentrations in some of them. It is not easy to standardise a medicine derived from herbal sources that can contain a large number of chemical constituents, with little or no evidence that could be responsible for the supposed or confirmed beneficial response.[74]
5. Dosage forms and Mode of Administration.	Conventional drugs are available in a variety of dosage types, including solid, semi-solid, liquid, and even gaseous. Tablets, pills, granules, powders, liquids, suspensions, emulsions, sprays, injections, and other forms of medication are	Herbal remedies are present in a variety of forms, including solid, semisolid, and liquid extracts, as well as fresh or dried herbs. They're used to treat chronic diseases like back pain and stress-related disorders that can be difficult to deal with. They can be taken by

	produced by the conventional medicinal method. They're given orally, subcutaneously, intramuscularly, inhaled, and in a variety of other ways.[75]	mouth, applied externally, or inhaled.[76]
6. The impact and choice of medicinal system globally.	People are returning to the use of herbal medicine, despite the fact that conventional medicine has been the most widely accepted system of medicine for many years. This is attributable to allopathic medicine's following drawbacks.[65,69] . • It just provides symptomatic relief from ailments. • It has a number of severe and aggravating side effects. • It is very expensive	Because of the following characteristics, herbal medicine such as ayurveda and homoeopathy are favoured in these types of settings: It is less costly and more fair.[77]. • Correlates directly to the patient's values • More easily available • Time has proven it's worth • It's thought to be more organic and safer. • They are thought to have fewer or no side effects.
7.Adverse Drug Reaction	Conventional drugs are also not free from adverse effects for example Usage for a long time NSAIDs in acute circumstances, it can lead to the development of gastric ulcers and bleeding. Usage for a long time antacids may lead to dose-dependent rebound hyperacidity. Anti helmintics cause abdominal pain, vomiting, dizziness, temporary hearing loss. Decongestants causes increased blood pressure,Headache, agitation, lethargy, and mouth dryness . Electrolytes ion causes Hypertension, lightheadedness and agitation, lethargy, swelling of the foot and eyelids, systemic fatigue, muscle spasms.	Herbal therapies aren't completely free of drug interactions. Any of the more widely used herbs can cause negative drug reactions like, St. John's Wort (Hypericum perforatum) causes stomach disturbances, allergic reactions, nausea, dizziness, photosensitivity, and confusion, while Ginkgo biloba causes accidental bleeding. Hypertension, cardiac arrhythmias, and myocardial infarction are all caused by Capsicum annuum. Anxiety is caused by ephedra, headaches and diarrhoea are caused by Vitex agnus (Chast tree fruit), and liver toxicity is caused by Piper methysticum..[78]

7. Herbs and their Interaction with Conventional drugs

In certain cases, the medications enhance each other's effects, and in others, unwanted side effects occur. Drug interaction is described as the result of two or more drugs being taken into the body at the same time. They acknowledged that herbal and conventional drugs also have distinct pharmacokinetic and pharmacodyanamic effects that can yield different therapeutic results, describing drug interaction as a significant factor to consider in healthcare. [79-81] Ginkgo biloba is used to treat Alzheimer's disease and increases bleeding when combined with aspirin. Kava is an anxiolytic that has a synergistic effect with benzodiazepines. [10] To prevent potentially dangerous medication reactions, thorough research should be conducted when taking herbal and orthodox drugs together. [79-81].

8. Need of pharmacovigilance

The WHO Collaborating Centre for International Drug Monitoring has recommended that proper scientific binomial names for herbs used in medicine be used, particularly in the coding of adverse reaction (AR) evidence (where this detail is available), for the purpose include accuracy when it comes to plant names in adverse reaction (AR) studies.[82]

This ensures that information from different international pharmacovigilance sources are comparable. Authors of published AR case reports should also provide information about the individual product(s) used, such as packaging and distributor information, specific ingredients, and the dose used. Analyses of the suspected substance utilised as diluted and impure, as well as genus recognition, if at all necessary, will be beneficial to published case reports.[77] Herbal medicines present unique challenges in terms of pharmacovigilance since they are accessible due to a large variety of sources, usually where there is no medical care provider is obtainable, and majority of the transactions are made in a traditional OTC atmosphere [83]. PvPI promotes the reporting of all suspected ADRs, whether they are well-known or unknown, serious or not, common or uncommon, regardless of whether there is a known causal association between the drug and the reaction. Allopathy, vaccines, alternative drugs, medical equipment, contrast media, and other ADRs may be recorded to the PvPI[84]. It is common knowledge that genetic factors take part in

deciding an person's vulnerability to harmful drug response, as well as applies for both natural and conventional medications. As a result, pharmacovigilance is an effective post-market security mechanism for to make sure the wellbeing of others of pharmaceuticals together with health dependent components. [85,86].

9.Conclusion:

A review of the literature on ayurvedic (herbal) medicine and allopathic medicine revealed the strengths and disadvantages of each system, and proposed combining the two to form an integrated solution that uses both systems of healthcare. This is because both systems have flaws, but combining their strengths yields positive results. Ayurvedic medicine places a greater emphasis on prevention. Individuals and countries alike depend on their health for survival and growth. Preventing, diagnosing, treating, and curing illnesses, as well as ensuring the general well-being of individuals and populations, requires effective health care. [66] With the growing popularity of herbal products, future global labelling practises should better resolve quality issues. For a better understanding of the use of herbal medicines, Processes should be organized, quality assurance reports on efficacy and safety are needed. [87]. As human cultures have progressed, various medical systems have grown and adapted in response to the society's needs. The two most popular systems of medicine used in health care for that reason are herbal and allopathic medicinal systems.

10.Reference:

1.Role of Pharmacovigilance in India: An overview

Sanvidhan G Suke, 1 ,* PrabhatKosta, 2 and Harsh Negi 3

Online J Public Health Inform. 2015; 7(2): e223Published online 2015 Jul 1.

doi: 10.5210/ojphi.v7i2.5595

2.McBride WG. 1961. Thalidomide and congenital abnormalities. *Lancet*. 278, 1358 10.1016/S0140-6736(61)90927-8 [CrossRef] [Google Scholar]

3.Bégaud B, Chaslerie A, Haramburu F. 1994. Organization and results of drug vigilance in France. *Rev EpidemiolSantePublique*. 42, 416-23. [PubMed] [Google Scholar]

4.WHO. The Importance of Pharmacovigilance, Safety Monitoring of medicinal products.World Health Organization 2002. [Google Scholar]

5. Shuka SS, Gidwani B, Pandey R, Rao SP, Singh V, et al. 2012. Importance of Pharmacovigilance in Indian Pharmaceutical Industry. *Asian J. Res. Pharm. Sci.* 2, 4-8. [Google Scholar]

6.Ongoing Challenges in Pharmacovigilance

- Gerald J. Dal Pan

Drug Safety volume 37, pages1–8(2014)

7.Pharmacovigilance of herbal medicines: Current state and future directions

SandeepShetti, C. Dinesh Kumar,1 Neeraj Kumar Sriwastava, and IndraPrakash Sharma

Pharmacogn Mag. 2011 Jan-Mar; 7(25): 69–73

doi: 10.4103/0973-1296.75905

8.Winslow LC, Kroll DJ, Herbs as medicines, Archives of Internal Medicine, 158, 1998, 2192-2199.

9.PHARMACOVIGILANCE OF HERBAL MEDICINES: AN INTANGIBLE APPROACH P. NainwalDevBhoomi Institute of Pharmacy and Research, Dehradun, Uttarakhand, India

IJPSR (2010), Vol. 1, Issue 11

10. Chauhan VS, Standardizing herbs and intermediatesnewerapproaches,ThePharma Review, 2, 2006, 37-44.

11. Use of Herbal Medicines and Implications for Conventional Drug Therapy Medical Sciences

12. Geneva: World Health Organization; 2003. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. [Google Scholar]

13. Bowdler J. *The Erice report.* Birmingham: W Lake; 1997. Effective communications in pharmacovigilance. [Google Scholar]

14.Pharmacovigilance related topics at the level of the International Conference on Harmonisation (ICH)
PriyaBahri PhD PanosTsintis FRCP (Ed)
First published: 01 November 2004
https://doi.org/10.1002/pds.1043

15. Pharmacovigilance: methods, recent developments and future perspectives Härmark L van Grootheest A.C European Journal of Clinical Pharmacology 2008; 64:743-52.

16. Gross CP, Mallory R, Heiat A, et al. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002; 137:10-6

17. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162:1682-8.

18. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice researchnetwork. Soc Psychiatry PsychiatrEpidemiol 2005; 40:27-35.

19. Wardell WM, Tsianco MC, Anavekar SN, et al. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J ClinPharmacol 1979; 19:85-94.

20. van Grootheest K, Olsson S, Couper M, et al. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004; 13:457-64.

21. van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004; 3:363-8.

22. van Grootheest AC, Passier JL, van Puijenbroek EP. [Direct reporting of side effects by the patient: favourable experience in the first year]. Ned TijdschrGeneeskd 2005; 149:529-33.

23. Edwards IR. Spontaneous reporting--of what? Clinical concerns about drugs. Br J ClinPharmacol 1999; 48:138-41**.**

24. Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4:929-48.

25. Bate A, Lindquist M, Edwards IR, et al. A data mining approach for signal detection and analysis. Drug Saf 2002; 25:393-7.

26. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25:381-92

27. Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance. European Commission Enterprise and Industry Directorate-general 2007. Brussels.

28. Strom BL (ed). Pharmacoepidemiology.4th edn 2005. Wiley, Chichester

29. Gelfand JM, Margolis DJ, Dattani H. The UK General Practice Research Database. In: Strom BL (ed) Pharmacoepidemiology. 4th edn 2005.Wiley, Chichester.

30. Parkinson J, Davies S, van Staa T. The General Practice Research Database: Now and the Future. In: Mann R, Andrews E (eds) Pharmacovigilance 2007. 2nd edn.Wiley, Chichester.

31. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27:871-81.

32. Leufkens HG, Urquhart J. Automated Pharmacy Record Linkage in the Netherlands. In: Strom BL (ed) Pharmacoepidemiology. 4th edn 2005.Wiley, Chichester.

33. Sturkenboom MCJM. Other databases in Europe for the Analytic Evaluation of Drug Effects. In: Mann R, Andrews E (eds) Pharmacovigilance. 2nd edn 2007.Wiley, Chichester.

34. Yerramilli A, Veerla S, Chintala E, Guduguntla M, Velivelli P. A Pharmacovigilance Study Using Tracer Techniques. Advances in Pharmacoepidemiolology Drug Safety. 2014; 3:165-167

35. . Salim M. The Current Perspective of Community Pharmacists towards Pharmacovigilance. Journal of Pharmacovigilance. 2015; 7:180-182.

36. Elhassan GO. Clinical Perspectives towards patient safety. Journal of Pharmacovigilance. 2015; 3:129-132.
37. Allabi AC, Nwokirke JA. Situational analysis of pharmacovigilance system in republic of benin. Journal of Pharmacovigilance. 2014; 2:136-138.
38. Patil AS. Pharmacovigilance in India. Journal of Pharmacovigiance, 2014; 2:119-121.

39. Pharmacovigilance Programme of India: Recent developments and future perspectives

Vivekanandan Kalaiselvan, Prasad Thota, and Gyanendra Nath Singh1
Indian J Pharmacol. 2016 Nov-Dec; 48(6): 624–628
doi: 10.4103/0253-7613.194855

40.Pharmacovigilance: Present status and future perspectives Dr. Alka Sawarkar, Dr. RK Sharma, Dr. Vidhi Gautam, Dr. K Shramankar and Dr. Neelam Dinodia
The Pharma Innovation Journal 2019; 8(8): 84-92

41. Srivastava P, Kumar P, Sharma A, Upadhya Y. A review Pharmacovigilance, Journal of Pharmacology and Toxicology. 2011; 1:56-57

42. Hugman B. The Erice declaration : the critical role of communication in drug safety. Drug Saf 2006; 29:91-3.

43. Adis International. The Erice Manifesto: for global reform of the safety of medicines in patient care. Drug Saf 2007; 30:187-90.

44. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12:17-29.

45. Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance. European Commission Enterprise and Industry Directorate-general 2007. Brussels.

46. Psaty BM, Burke SP. Protecting the health of the public--Institute of Medicine recommendations on drug safety. N Engl J Med 2006; 355:1753-5.

47. McClellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N Engl J Med 2007; 356:1700-2.

48.Coombes R. FDA tightens its grip on drug regulation. BMJ 2007; 334:290-1.

49. Zwillich T. US lawmakers tackle safety reforms at the FDA. Lancet 2007; 369:1989-90.

50. Hennessy S, Strom BL. PDUFA reauthorization-drug safety's golden moment of opportunity? N Engl J Med 2007; 356:1703-4.
51. Hugman B. The Erice declaration : the critical role of communication in drug safety. Drug Saf 2006; 29:91-3
52. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12:17-29.
53. Sim I, Chan AW, Gulmezoglu AM, et al. Clinical trial registration: transparency is the watchword. Lancet 2006; 367:1631-3.
54. Human Medicines - EMEA Pre-Submission Guidance. European Medicines Agency 2005. Available via http://www.emea.europa.eu/htms/human/presub/list.htm Accessed Dec 18, 2007.
55. Guideline on Risk management Systems for Medicinal Products for Human Use. European Medicines Agency 2005. Available via http://www.emea.europa.eu/pdfs/human/euleg/9626805en. pdf Accessed Dec 18, 2007
56. Strategy to better protect public health by strengthening and rationalising EU pharmacovigilance. European Commission Enterprise and Industry Directorate-general 2007. Brussels
57. de Langen J, van Hunsel F, Passier A, et al. Three Years of Experience with ADR Reporting by Patients in the Netherlands. [In Press] Drug Saf 2008.
58. Härmark L, Kabel JS, van Puijenbroek EP, et al. Web-Based Intensive Monitoring, a New Patient Based Tool for Early signal Detection. [Abstract] Drug Saf 2006; 29:911-1010.
59.Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22:298-305.
60. Ghewari P, Salunke S, Bhatiya N, Killedar S. Strategies and current scenario of pharmacovigilance in India. Journal of Pharmacovigilance. 2014; 1:122-134.
61. Borja-Oliveira CR. Alcohol-Medication interactions: The Acetaldehyde Syndrome. Journal Pharmacovigilance. 2015; 2:145-147.
62. Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. adverse drug reactions reporting culture in pharmacovigilance programme of India. Indian Journal of Medical Research. 2014; 5:114-117.

63. Bhargava, J., Khan, Z. Y. (2012). Comparative evaluation of the efficacy and the side effects of imipramine, sertraline and an ayurvedic formulation in patients of depression. J. Clin. Diag. Res., 6(2), 220-225.

64.Elvin-Lewis M. (2001), Should we be concerned about herbal remedies. J. Ethnopharmacol., 75(2), 141-64.

65. Kumar, K., Rai, A. K. (2011). A Review on Conventional and Ayurvedic medicine: Need of Time for their Synergistic Effects. Int'l J. Pharm. Life Sc., 1, 13

66. Comparitive Analysis of Herbal and Allopathic Treatment systems Aminu Saleh Ahmad1 , Ruchi Sharma2 European Journal of Molecular & Clinical Medicine Volume 07, Issue 07, 2020

67. Vipula (2014). Ayurveda & Allopathy: An Integrated Approach. Guru Drone J. Pharmacy. Res., 2(4), 17-22.

68.Galor, S. W. and Benzie, I. F. F. Herbal Medicine: An Introduction to Its History, Usage, Regulation, Current Trends, and Research Needs. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd Edition, p67-71.

69.Jawla, S.; Gupta, A. K.; Singla, R. Gupta, V. (2009). General Awareness and Relative Popularity of Allopathic, Ayurvedic and Homeopathic Systems J. Chem. Pharm. Res., 1(1),105-112

70. Miller L.G. (1998). Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Intern. Med., 158(20): 2200-11.

71. Gogtay, N. J., Bhatt, H. A., Dalvi, S. S.; Kshirsagar, N. A. (2002). The use and safety of non-allopathic indian medicines. Drug Safety, 25(14), 1005-19.

72. Calixto, J. B. (2000). Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz. J. Med. Biol. Res., 33(2), 179-89.

73. Pal, S. K. and Shukla, Y. (2003). Herbal medicine current status and the future. Asian Pac. J. Cancer Prev., 4, 281-288.

74. Rani, M. S.; Pippalla, R. S.; Mohan, G. K.; Gaikwadi, S. B.; Prasad, B. (2014). A Comparative Quality of Life Assessment of Herbal Drugs with Allopathic Drugs for the Treatment of Diabetic Complications. Pharm. Crops, 5(Suppl. 1: M7), 77-84

75. Khar, R. K., Vyas, S. P., Ahmad, F. J., Jain, G. K. Lachman/Liebermans: the theory and practice of industrial pharmacy. CBS Publishers and Distributors, New Delhi, Fourth Edition, 2013.

76. Onifade, A. A., Jewell, A. P., Ajade, T. A., Rahamon, S. K., Ogunrin, O. O. (2013). Effectiveness of a herbal remedy in six HIV patients in Nigeria. J. Herb. Med., 3(3), 99- 103

77.Pharmacovigilance of Herbal Products in India

P Wal, A Wal, S Gupta, G Sharma, and AK Rai
J Young Pharm. 2011 Jul-Sep; 3(3): 256–258
doi: 10.4103/0975-1483.83780

78. Kuhn MA, Herbal remedies: drug-herb interactions, Critical Care Nurse, 22, 2002, 22-32.

79.Monish, S., Bhupinder, K., Sudeep, B. (2016). Herbs and their Interaction with Allopathic Drugs- a review. Pharmatutor Art, 1646.

80. Singh, A., Lin, Y., Liu, W., Yu, S., Pan, J., Ren, C., & Kuanhai, D. (2014). Plant derived cationic dye as an effective corrosion inhibitor for 7075 aluminum alloy in 3.5% NaCl solution. Journal of Industrial and Engineering Chemistry, 20(6), 4276-4285

81. Prabhakar, P. K., Prasad, R., Ali, S., & Doble, M. (2013). Synergistic interaction of ferulic acid with commercial hypoglycemic drugs in streptozotocin induced diabetic rats. Phytomedicine, 20(6), 488-494

82. Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety sassessment. *Toxicol Appl Pharmacol.* 2010;243:198–216. [PubMed] [Google Scholar]

83. Current Trends in Herbal Medicines Lakshmana Rao Atmakuri*and Suneetha Dathi *Department of Pharmaceutical Analysis, Shri Vishnu College of Pharmacy,Vishnupur, Bhimavaram, A.P., India.

84. Pharmacovigilance in drugs used in the treatment of drug dependence

Anusha Thota, Prasad Thota,1 Vivekanandan Kalaiselvan,1 Siddharth Sarkar, and Gyanendra Nath Singh
Indian J Psychiatry. 2017 Jul-Sep; 59(3): 393–395.
doi: 10.4103/psychiatry.IndianJPsychiatry_268_16

85.Chan TYK, Monitoring the safety of herbal medicines, Drug Safety, 17, 1997, 209-215.

86.PHARMACOVIGILANCE OF HERBAL MEDICINES: AN INTANGIBLE APPROACH

P. Nainwal

Dev Bhoomi Institute of Pharmacy and Research, Dehradun, Uttarakhand, India

87. Alam S, Ali R, Akhter S, Haque A, Ansari SH, Role of herbals in drug delivery system, The Pharma Review, 6, 2007, 106-107.